Case report

Hermansky–Pudlak syndrome type 4 with interstitial pneumonia

Yoshihiko Sakata*, Kodai Kawamura, Kazuya Ichikado, Moritaka Suga, Masakazu Yoshioka

Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Kumamoto 861-4193, Japan

1. Introduction

Hermansky–Pudlak syndrome (HPS) is an autosomal recessive disorder characterized by oculocutaneous albinism, bleeding tendency secondary to platelet dysfunction, and lysosomal ceroid accumulation.1 Ceroid, which accumulates sporadically and slowly in the lungs, is not crucial for a diagnosis of HPS, but primarily accounts for the significant associated morbidity. Pulmonary fibrosis, usually manifesting in the third and fourth decades of life, accounts for premature death in 50% of HPS patients, which generally occurs by the fifth decade.2,3

Nine different genes cause HPS in humans.4,5 Among them, the HPS-1 gene shows the highest frequency of mutation. HPS-1 mutation represents the classical disease, which manifests with all the typical complications of HPS. HPS-4 disease is considered to resemble HPS-1, but only a few case of HPS-4 have been reported.6–9 HPS-1 and HPS-4 individuals show the greatest degree of pulmonary involvement, with an estimated 80% of HPS-1 subtypes afflicted.5,9 Here, we report a case of HPS presenting with interstitial pneumonia and exhibiting a novel HPS-4 gene mutation.

2. Case report

A 58-year-old man was admitted to our hospital because of progressive dyspnea. He had experienced shortness of breath for years, but had been well until 4 weeks earlier. He showed congenital albinism, amblyopia, and photodermatosis, but had received no previous medication for the condition. He was a massager, drank distilled spirits about 250 ml/day, and had smoked occasionally. The patient’s family history revealed that his parents were cousins. There is no history of albinism in his family, but his father died of pulmonary disease at approximately 50 years.

On admission, body temperature was normal range. Pulse rate was 95 beats per minute, blood pressure was 110/60 mmHg, respiratory rate was 25 ~ 30 breaths per minute, and oxygen saturation was 82% in ambient air, increasing to 95% with oxygen supplementation (3 l) by nasal cannula. Physical examination on admission revealed blond hair, blond body hair, pale white skin, and erythema on the upper and lower extremities and neck (Fig. 1). The patient had amblyopia, strabismus, and horizontal nystagmus. Fine crackles in the bilateral lower lung fields were detected, but heart sounds were normal. He had neither clubbed finger nor edema. The results of abdominal and neurological examinations were normal.

Laboratory results on admission are shown in Table 1. Although the patient was anemic, white blood cell and platelet counts were normal, and coagulopathy fibrinogenolysis was also normal. Blood
chemistry showed elevation of lactate dehydrogenase (LDH), sialylated carbohydrate antigen (KL-6) levels. Chest radiography showed bilateral volume loss, and the lower lobes showed dominantly diffuse linear and reticular opacity with ground-glass opacity in both lung fields. Chest CT showed bilateral diffuse ground-glass opacity associated with mild traction bronchiectasis and reticulation which was consistent with acute exacerbation on chronic fibrosing interstitial pneumonia (Figs. 2 and 3). A trans-thoracic echocardiogram showed mild right ventricular hypokinesis, but left ventricular function was normal. There were no clinical signs of pulmonary infection.

We diagnosed acute exacerbation of interstitial pneumonia, and treated with high-dose corticosteroid (methylprednisolone, 1000 mg/day for three days followed by oral prednisone at a dose of 40 mg/day). His clinical symptoms and findings on high-resolution CT slowly improved; therefore, additional corticosteroid pulse therapy and pirfenidone were administered for fibrosing interstitial pneumonia. Subsequently, his breathing condition, clinical marker levels, and chest imaging results stabilized, but he needed long-term oxygen therapy.

Because the patient had interstitial pneumonia with albinism, we investigated the possibility of HPS. Therefore, bone marrow biopsy, platelet aggregation test, and genetic diagnosis were performed to diagnose HPS. A platelet aggregation test revealed a lack of secondary wave aggregation with normal first aggregation of ADP (Table 1). Bone marrow biopsy showed that macrophages contained a ceroid-like material (Fig. 4). We performed mutation analysis of HPS-1 (GenBank accession no. NM_000195.3) and HPS-4 (GenBank accession no. NM_022081.4) gene (Supplementary File). We identified a novel mutation, c.1858C>T (p.Q620X), in HPS4 homozygously in the patient and heterozygously in his mother, his sister and his daughter (Fig. 5). The diagnosis of HPS-4 was confirmed by this gene analysis.

The corticosteroid dose was gradually tapered and then discontinued as the patient’s condition became stable. Pirfenidone dosage was increased gradually without harmful adverse effects. Although chest CT performed after one year of treatment demonstrated progression of bilateral diffuse ground-glass opacity with mild traction bronchiectasis (Fig. 3), response to therapy was considered “stable” according to the ATS/ERS criteria by using pulmonary functional indices (Table 2).

3. Discussion

We present a rare case of HPS-4 with interstitial pneumonia. High-dose corticosteroid treatment was effective for acute exacerbation of IP and pirfenidone has been used for 1 year.

HPS is a rare autosomal recessive disorder. It is characterized by oculocutaneous albinism, platelet dysfunction, and accumulation of ceroid-like materials and is associated with interstitial pneumonia. HPS is common only in northwest Puerto Rico. However, it is extremely rare in other regions, occurring with a prevalence of 1 in 500,000–1,000,000 persons. Among these cases, nearly all

Table 1
Laboratory findings on admission.

| Blood analysis | Blood gas analysis (room air) |
|----------------|-----------------------------|
| WBC 6300/μL    | pH 7.476                    |
| Hb 108 g/dL    | PaO₂ 40.8 mmHg              |
| Ht 37.3%       | PaCO₂ 35.6 mmHg             |
| Plt 28.6 × 10⁴/μL | HCO₃ 25.9 mmol/L             |
| PT (%) 76.7%   |                             |
| APTT (%) 72.2% | Pulmonary function test (analyzed on day8) |
| AT III 91%     | VC                           |
| FDP 3.0 μg/mL  | 2.28 L                      |
| Bleeding time 3 min | 62%                          |
| BUN 7.7 mg/dL  | FEV₁,α                      |
| CRE 0.89 mg/dL | 2.06 L                      |
| AST 37 IU/L    | FEV₁,DL-G                   |
| ALT 36 IU/L    | 93.7%                       |
| LDH 371 IU/L   | Platelet aggregation test    |
| ESR 1 h 50 mm, 2 h 73 mm | ADP (3.0 μM) | 76% |
| CRP 1.82 mg/dL | Collagen (2.0 μg/mL)        |
| β-D-glucan < 5.0 pg/mL | 44%                  |
| IgG 1383 mg/dL |                             |
| IgA 740 mg/dL  |                             |
| IgM 87 mg/dL   |                             |
| BNP 78.5 pg/mL |                             |
| SP-D 168 ng/mL |                             |
| KL-6 1550 U/mL |                             |
| ANA (--)      |                             |
| PR3-ANCA, MPO-ANCA (--) |                   |
patients show HPS-1, and HPS-4 is extremely rare, so HPS-4 has never been reported in Japan. The pathogenesis of HPS has been currently investigated, but many parts remain unexplained.\textsuperscript{13–17}

The discovery of the HPS-4 subtype in 2002 was followed by examination of the HPS-4 mouse mutant.\textsuperscript{8} Bachli et al. have reported the only case of HPS-4 with IP.\textsuperscript{9} According to previous reports, the phenotype of HPS-4 is similar to that of HPS-1, and the mean age of onset of pulmonary symptoms in patients with mutations in the HPS1 gene is about 30–40 years.\textsuperscript{18} In our case, onset was relatively late and severity of fibrosis was moderate. Anderson et al. reported clinical features of 7 patients with documented HPS-4 mutations, ranging in age from 3 to 61 years.\textsuperscript{6} Three of the 7 patients had restrictive lung disease; one had severe pulmonary fibrosis and died of lung disease. According to Avila et al., patients with mutations in the HPS-1 gene had more severe lung disease than patients without HPS-1 gene mutations.\textsuperscript{3} The clinical course of HPS-4 may be slightly different from that of HPS-1 based on the previous reports and ours.

Regarding the treatment of interstitial pneumonia associated with HPS, corticosteroids or other immunosuppressive drugs generally have not been effective,\textsuperscript{18} but there have been no trials examining the efficacy of steroid treatment. In our case, respiratory status and findings on CT scans clearly improved in the first 2

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Fig. 3. A–B, CT scan of right lung at time of admission. C–D, same slices of right lung 2 months later, showing improvement of ground-glass opacity and reticulonodular pattern as the result of treatment. E–F, same slices of right lung at 1 year after admission, showing gradual progression of disease.}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{Fig. 4. Bone marrow biopsy showing macrophages containing ceroid-like materials.}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure5.png}
\caption{Fig. 5. Sequence analysis of exon 13 in HPS4 gene using genomic DNA samples from the patient and his mother reveals the novel mutation, c.1858C > T (p.Q620X), homozygously in the patient and heterozygously in his mother. The mutation was also detected in his sister and his daughter (data not shown).}
\end{figure}
weeks. We believe that high-dose steroid therapy contributed to the patient’s improvement after the initial deterioration of IP. High-dose steroid therapy should be considered as a treatment option in these situations, because there is no alternative effective therapy during an acute exacerbation of IP.

Subsequently, we added pirfenidone and gradually reduced the corticosteroid dose. Gahl et al. reported that pirfenidone may slow the progression of pulmonary fibrosis due to HPS–1. On the other hand, recently, a small number of randomized controlled trials has been published that did not show slowing of decline in pulmonary function in small numbers. Thus, the utility of pirfenidone for HPS hand, recently, a small number of randomized controlled trials has revealed characteristic macrophages containing ceroid pigments and foamy swelling of pneumocytes. Further investigation of genetic analysis and enrollment of these cases is indispensable for appropriate treatment strategies.

In conclusion, our findings suggest that HPS should be suspected in patients with albinism and interstitial pneumonia. High-dose corticosteroid may be useful in cases of acute exacerbation of interstitial pneumonia due to HPS-4, and pirfenidone might be effective in treatment for progressive HPS-4 pulmonary fibrosis.

Acknowledgment

We greatly appreciate the assistance of Takihiko Kamio in the Division of Pathology Medicine, Saikeikai Kumamoto Hospital. Gene analysis of this case was performed by Department of Dermatology, Nagoya University Graduate School of Medicine.

Table 2

| Blood analysis | Reference | Admission | 3 Months | 6 Months | 9 Months | 12 Months |
|----------------|-----------|-----------|----------|----------|----------|----------|
| LDH (IU/L)     | 112–213   | 371       | 367      | 358      | 318      | 330      |
| KL-6 (U/mL)    | <500      | 1550      | 1250     | 2520     | 1790     | 1620     |
| Pulmonary function tests | | | | | | |
| VC (L)         | 2.28      | 2.71      | 2.27     | 2.37     |          |          |
| 3DLCO (%)      | No data   | 36.9      | 25.2     | 28.2     |          |          |

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.rmcr.2013.04.002.

References

1. Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow. Blood 1959;14:162–9.
2. Shotelersuk V, Dell’Angelica EC, Hartnell L, Bouflocino JS, Gahl WA. A new variant of Hermansky–Pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am J Med 2000;108:423–7.
3. Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome. Mol Genet Metab 2002;76:234–42.
4. Huizing M, Gahl WA. Disorders of vesicles of lysosomal lineage: the Hermansky–Pudlak syndromes.Curr Med Res Opin 2002;2:451–67.
5. Anderson PD, Huizing M, Claassen DA, White J, Gahl WA. Hermansky–Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum Genet 2003;113:10–7.
6. Wei ML, Hermansky–Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res 2006;19:19–42.
7. Cullinane AR, Curry JA, Carmona-Rivera C, Summers CG, Ciccone C, Cardillo ND, et al. A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky–Pudlak syndrome type 9. Am J Hum Genet 2011;88:778–87.
8. Gahl WA, Brantly M, Kaiser-Kupfer MI, Iwata F, Hazelwood S, Shotelersuk V, et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky–Pudlak syndrome). N Engl J Med 1998;338:1258–64.
9. Suzuki T, Li W, Zhang Q, Karim A, Novak EK, Sviderskaya EV, et al. Hermansky–Pudlak syndrome is caused by mutations in HPS4, the mouse homolog of the mouse light ear gene. Nat Genet 2003;30:321–4.
10. Bachl EB, Brack T, Eppler E, Stammach T, Trieb BM, Huizing M, et al. Hermansky–Pudlak syndrome type 4 in a patient from Sri Lanka with pulmonary fibrosis. Am J Med Genet A 2004;127A:201–7.
11. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. American Thoracic Society (ATS), and European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646–64.
12. Witkop CJ, Nuñez Babcock M, Rao GH, Gaudier F, Summers CG, Shanahan F, et al. Albinism and Hermansky–Pudlak syndrome in Puerto Rico. Mol Asoc Med P R 1990;82:313–9.
13. Huizing M, Heliup-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008;9:359–86.
14. Falcón-Pérez JM, Nazarian R, Sabatti C, Dell’Angelica EC. Distribution and dynamics of Lamp1-containing endocytic organelles in fibroblasts deficient in BLOC-3. J Cell Sci 2005;118:5243–55.
15. Young LR, Pasula R, Gullerman PM, Deutsch GH, McCormack FX. Susceptibility of Hermansky–Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis. Am J Respir Crit Care Med 2000;161:646–64.
16. Yoshiioka Y, Kumasaka T, Ishidoh K, Komamm M, Mitani K, Hosokawa Y, et al. Fibrotic and stromal changes in the lungs of Hermansky-Pudlak syndrome model pale ear mice. Pathol Int 2004;54:322–31.
17. Mahavadi P, Korfei M, Henneke I, Liebisch G, Schmitz G, Gochuico BR, et al. Epithelial stress and apoptosis underlie Hermansky–Pudlak syndrome-associated interstitial pneumonia. Am J Respir Crit Care Med 2010;182:207–19.
18. Pierson DM, Ionescu D, Qing G, Yonan AM, Parkinson K, Colby TC, et al. Pulmonary fibrosis in Hermansky–Pudlak syndrome: a case report and review. Respiration 2006;73:382–95.
19. O’Brien K, Troendle J, Gochuico BR, Markello TC, Salas J, Cardona H, et al. Pirfenidone for the treatment of Hermansky–Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 2011;103:128–34.
20. Lederer DJ, Kawut SM, Sonett JR, Vakiani E, Seward Jr SL, White JC, et al. Successful bilateral lung transplantation for pulmonary fibrosis associated with the Hermansky–Pudlak syndrome. J Heart Lung Transplant 2005;24:1697–9.
21. Avila NA, Brantly M, Premkumar A, Huizing M, Dwyer A, Gahl WA. Hermansky–Pudlak Syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. Am J Roentgenol 2002;179:887–92.